Program
ulotaront
Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.
Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.
Drug pageSEP-363856: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 265 open or running | phase 3since Aug 26, 2019 | Oct 24, 2013 | Mar 2028phase 3 · NCT07225712 |
| Sumitomo Pharmaits history only | 40 open or running | phase 3since Mar 29, 2021 | Nov 22, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Oct 24, 2013.
- Dec 19, 2020Named ulotarontINNProposed as its International Nonproprietary Name in WHO's List 124 · before, SEP-363856, SEP363856
- Mar 29, 2021Phase 3 study in SchizophreniaSumitomo Pharma · NCT04825860 · 83 enrolled · China, Japan, Philippines and more
- Apr 26, 2021Phase 1 study in SchizophreniaOtsuka · NCT04865835 · 21 enrolled · United States
- Aug 10, 2021Phase 1 study in NarcolepsyOtsuka · NCT05015673 · 18 enrolled · United States
- Apr 27, 2022Phase 3 study in SchizophreniaSumitomo Pharma · NCT05359081 · 68 enrolled · Japan
- May 24, 2022Phase 1 study in SchizophreniaOtsuka · NCT05402111 · 31 enrolled · United States
- Jul 6, 2022Phase 1 study in SchizophreniaOtsuka · NCT05463770 · 15 enrolled · United States
- Aug 15, 2022Phase 1 study in SchizophreniaOtsuka · NCT05542264 · 19 enrolled · United States
- Oct 10, 2022Phase 2 study in Depressive Disorder, MajorOtsuka · NCT05593029 · 929 enrolled · United States, Bulgaria, Canada and more
- Nov 16, 2022Phase 3 study in SchizophreniaOtsuka · NCT05628103 · 101 enrolled · United States
- Feb 6, 20232 phase 3 studiesOtsuka · NCT05729373, NCT05741528
- Apr 27, 2023Phase 1 study in SchizophreniaOtsuka · NCT05848700 · 60 enrolled · United States
- Feb 27, 2025Phase 3 study in SchizophreniaOtsuka · NCT06894212 · 538 enrolled · United States, Japan
- Nov 5, 2025Phase 3 study in SchizophreniaOtsuka · NCT07225712 · 100 planned · Japan
- Aug 6, 20263 phase 3 studies in Generalized Anxiety DisorderOtsuka · NCT07759128, NCT07767903, NCT07786454
Ahead
- Mar 2028Primary completion: phase 3 study in SchizophreniaOtsuka · NCT07225712
- Oct 25, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07767903
- Dec 6, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07759128
- May 26, 2029Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07786454
TargetBeta
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07786454Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | May 26, 2029 | 1,120 |
| NCT07767903Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | Oct 25, 2028 | 384 |
| NCT07759128Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | Dec 6, 2028 | 576 |
| NCT07225712Schizophrenia · Japan | 3 | Recruiting | Otsuka | Mar 2028 | 100 |
| NCT06894212Schizophrenia · United States, Japan | 3 | Active, not recruiting | Otsuka | Oct 20, 2026 | 538 |
| NCT05848700Schizophrenia · United States | 1 | Completed | Otsuka | Mar 15, 2024 | 60 |
| NCT05741528Schizophrenia · United States | 3 | Completed | Otsuka | Sep 23, 2024 | 75 |
| NCT05729373Generalized Anxiety Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | Otsuka | Sep 26, 2025 | 434 |
| NCT05628103Schizophrenia · United States | 3 | Completed | Otsuka | Apr 1, 2024 | 101 |
| NCT05593029Depressive Disorder, Major · United States, Bulgaria, Canada and more | 2 | Completed | Otsuka | Nov 6, 2025 | 929 |
| NCT05542264Schizophrenia · United States | 1 | Completed | Otsuka | Feb 12, 2024 | 19 |
| NCT05463770Schizophrenia · United States | 1 | Completed | Otsuka | Aug 22, 2023 | 15 |
| NCT05402111Schizophrenia · United States | 1 | Completed | Otsuka | Sep 27, 2023 | 31 |
| NCT05359081Schizophrenia · Japan | 3 | Terminated | Sumitomo Pharma | Mar 21, 2024 | 68 |
| NCT05015673Narcolepsy · United States | 1 | Completed | Otsuka | May 26, 2015 | 18 |
| NCT04865835Schizophrenia · United States | 1 | Completed | Otsuka | May 3, 2022 | 21 |
| NCT04825860Schizophrenia · China, Japan, Philippines and more | 3 | Terminated | Sumitomo Pharma | Oct 12, 2023 | 83 |
| NCT04369391Schizophrenia · United States | 1 | Completed | Otsuka | Nov 10, 2020 | 150 |
| NCT04325737Schizophrenia · Japan | 1 | Completed | Sumitomo Pharma | Aug 7, 2020 | 13 |
| NCT04115319Schizophrenia · United States, Romania, Russia and more | 3 | Completed | Otsuka | Dec 30, 2022 | 305 |
| NCT04109950Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Terminated | Otsuka | Nov 9, 2023 | 463 |
| NCT04092686Schizophrenia · United States, Bulgaria, Croatia and more | 3 | Completed | Otsuka | Jun 14, 2023 | 464 |
| NCT04072354Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Completed | Otsuka | May 12, 2023 | 463 |
| NCT04038957Schizophrenia · United Kingdom | 1 | Completed | Otsuka | Jun 6, 2023 | 22 |
| NCT03370640Schizophrenia · Japan | 1 | Completed | Sumitomo Pharma | Sep 20, 2018 | 24 |
| NCT02970929Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Otsuka | Jan 29, 2019 | 157 |
| NCT02969369Parkinson Disease Psychosis · United States | 2 | Completed | Otsuka | Apr 20, 2020 | 39 |
| NCT02969382Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Otsuka | Jul 31, 2018 | 245 |
| NCT01994473Schizophrenia · United States | 1 | Completed | Otsuka | Dec 2014 | 48 |
| NCT01972711Schizophrenia · United Kingdom | 1 | Completed | Otsuka | Jul 2015 | 105 |
How it is read
Names in the registry
- “SEP-363856”, 24 entries
- “SEP-363856 75mg”, 2 entries
- “SEP363856”, 2 entries
- “SEP-363856 100mg”, 1 entry
- “SEP-363856 50mg”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 23 studies
- Generalized Anxiety Disorder, 4 studies
- Depressive Disorder, Major, 1 study
- Parkinson Disease, 1 study
- Narcolepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.